ClinicalTrials.gg
RecruitingNCT07214337Updated Nov 12, 2026

Digital Inhaler Use in Obstructive Lung Disease Care

An interventional study of Digital Inhaler Attachment in Chronic Obstructive Airways Disease Exacerbated and Chronic Obstructive Airway Disease, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Planned enrollment
837th of 1,039
20 · median 100
Started
2026
with 40 others
No phase
395 of 1,280
52 open now
Primary completion
2027-01
later than 57 of 173 live
Registered
1,233rd of 1,280
by date

Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 837th largest by planned enrollment of the 1,039 interventional ones that give a count, is one of 41 that started in 2026, is one of 395 with no phase, reaches primary completion later than 57 of the 173 other live ones, and was the 1,233rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

133 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

This is a pilot study to evaluate the role digital inhaler technology on patients with obstructive lung disease in preventing admissions and exacerbation, as well as improving symptom control. The primary objective is to evaluate feasibility of study protocol, patient recruitment, and patient retention with goal recruitment of 20 participants, 60% recruitment success, and 60% retention rate for 6 months duration. The secondary objectives are the evaluation of patient admission rate, exacerbation rates, and symptoms control with use of digital inhaler technology The subject population will be patients with physician diagnosed obstructive lung disease.

03

Conditions studied

  • Chronic Obstructive Airways Disease Exacerbated
  • Chronic Obstructive Airway Disease

Keywords

  • Chronic Obstructive Airways Disease
  • COPD
  • COPD Exacerbation
  • Severe COPD
  • Moderate COPD
  • Severe Chronic Obstructive Airways Disease
  • Moderate Chronic Obstructive Airways Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any sex
  • Over the age of 18 years.
  • Physician-diagnosed obstructive lung disease
  • Speak, read, and understand English.
  • The current study is a feasibility pilot. Based on the results of the study, future studies will include non-English speakers as well.
  • Able to understand study requirements and comply with study procedures.
  • Ability to operate a smartphone or tablet (for questionnaire and symptoms input).
  • Patients who use either a DPI or an MDI device as controller medications. Medications will not be changed by the study team.

Exclusion criteria

Exclusion Criteria:

  • Physically disabled such that they are incapable of using digital devices or metered dose inhalers.
  • Suffer from any visual, hearing or cognitive impairment that cannot be corrected enough to operate the devices properly. Mild/moderate vision loss and mild hearing loss may be included with appropriate corrective measures that do not affect the device usage.
  • Suffering from serious uncontrolled medical conditions that may interfere with study conduct.
  • Inability or unwillingness of the participant to give written .
  • Pregnant women (due to complicated physiology)
  • The current study is a feasibility pilot. Based on the results of the study, future studies will likely include pregnant patients as well.
  • Prisoners
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Digital Inhaler Attachment for Regular Care

    This group of patients will be provided interactive device that provides inhaler coaching for to use for 6 month duration.

    Device: Digital Inhaler Attachment

Interventions

  • DeviceDigital Inhaler Attachment

    This intervention is the attachment of a digital device to provide patient with coaching for optimal inhaler use and technique, as well as monitoring of patient use of inhaler to patient and health care team. Patient will continue to use inhalers prescribed as per usual care for management of COPD.

06

What researchers measure

Primary outcomes

  1. Participant Recruitment Percentage

    The investigators will be looking at what percentage of patients approached for recruitment choose to participate in the study. Accrual rate will be computed as the proportion of subjects enrolled as a function of the number of subjects screened.

    Time frame: 6 months

  2. Participant Retention Percentage

    The investigators will also be looking at what percentage patient who choose to participate remain participating for the full 6-month duration of the study period. The retention rate over the full 6-month period of follow-up will be computed among enrolled subjects.

    Time frame: 6 months

Secondary outcomes

  1. Re-admission Rate

    Hospital re-admission rate for COPD exacerbation during study period

    Time frame: 6 months

  2. COPD Exacerbation Rates

    Rates of COPD exacerbation after intervention during study period

    Time frame: 6 months

  3. Symptom Control

    Overall symptoms control of COPD after intervention during study period. This will utilize the COPD Assessment Test. Scores with this test can range from 0 to 40, with higher score representing worse severity of disease and worse symptom control.

    Time frame: 6 months

  4. Satisfaction with Device Assessed with Questionnaire

    Assessment of patient satisfaction with use of device utilizing questionnaire to be administered at the conclusion of the study.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 2 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

Start moved once since we started tracking on Sep 25, 2026: Nov 2025 → Nov 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 9, 2025
StartEst.
Nov 10, 2026was Nov 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
Cedars-Sinai Medical Center is now Recruiting
Nov 12, 2026
Start date
Nov 1, 2025→Nov 10, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    Cedars-Sinai Medical Center is now Recruiting
    Start date Nov 1, 2025→Nov 10, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07214337
Collaborators
Breathe California, Los Angeles County
Responsible party
Sara Ghandehari (Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center) — Principal investigator
First posted
Oct 9, 2025
Start date
Nov 10, 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Vinita Kusupati, MD
Contact
vinita.kusupati@cshs.org
14016512622
Sara Ghandehari, MD
Contact
sara.ghandehari@cshs.org
Sara Ghandehari, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion